Zoledronic acid in the management of metastatic bone disease

References

• BerensonJRRecommendations for zoledronic acid treatment of patients with bone metastasesOncologist200510526215632252
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo controlled phase III studiesBr J Cancer2004901133715026791
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMROn behalf of the MF 4625 study groupIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol200314139940512954579
   PubMed Web of Science ®Google Scholar
• BoissierSFerrerasMPeyruchaudOBisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasesCancer Res20006029495410850442
   PubMed Web of Science ®Google Scholar
• BoissierSMagnettoSFrappartLBisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matricesCancer Res199757389049307266
   PubMed Web of Science ®Google Scholar
• CaseyRLoveWMendozaCZoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy2006Presented at 2006 Multidisciplinary Prostate Cancer SymposiumFebruary 24–26, 2006San Francisco, Calif Abstract #184
   Google Scholar
• ClemonsMJDranitsarisGOoiWSPhase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event for progressive bone metastases despite first-line bisphosphonate therapyJ Clin Oncol200624489590017001071
   PubMed Web of Science ®Google Scholar
• ColemanREMajorPLiptonAPredictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidJ Clin Oncol20052349253515983391
   PubMed Web of Science ®Google Scholar
• CummingsSRBatesDBlackDMClinical use of bone densitometry: scientific reviewJAMA200228818899712377088
   PubMed Web of Science ®Google Scholar
• DaniellHWOsteoporosis after orchiectomy for prostate cancerJ Urol1997157439448996327
   PubMed Web of Science ®Google Scholar
• FaulknerKGBone matters: are density increases necessary to reduce fracture risk?J Bone Miner Res200015183710703919
   PubMed Web of Science ®Google Scholar
• FlaniganRCCampbellSCClarkJIMetastatic renal cell carcinomaCurr Treat Options Oncol200343859012941198
   PubMedGoogle Scholar
• GarneroPBuchsNZekriJMarkers of bone turnover for the management of patients with bone metastases form prostate cancerBr J Cancer2000828586410732759
   PubMed Web of Science ®Google Scholar
• GreenJRMullerKJaeggiKAPreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compoundJ Bone Miner Res19949745518053405
   PubMed Web of Science ®Google Scholar
• HaradaMIidaMYamaguchiMAnalysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy casesAdv Exp Med Biol1992324173821492615
   PubMedGoogle Scholar
• HiganoCSUnderstanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinicianUrol Clin N Am20043133152
   PubMed Web of Science ®Google Scholar
• HiganoCSBone loss and the evolving role of bisphosphonate therapy in prostate cancerUrol Oncol200321392814670551
   PubMed Web of Science ®Google Scholar
• HoffAOTothBAltundagKOsteonecrosis of the Jaw in Patients Receiving Intravenous Bisphosphonate TherapyJCO200624suppl 18528
   Google Scholar
• International Osteoporosis FoundationThe facts about osteoporosis and its impact [online] Accessed January 10 2007 URL: http://www.iofbonehealth.org/facts
   Google Scholar
• IsraeliRSRosenbergSSaltzsteinDBone mineral density in patients with prostate cancer undergoing initial androgen-deprivation therapyJ Urol2006175Suppl 4134 Abstract 410
   Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol20052333142115738536
   PubMed Web of Science ®Google Scholar
• KristensenBEjlertsenBGroenvoldMOral clodronate in breast cancer patients with bone metastases: a randomized studyJ Intern Med1999246677410447227
   PubMed Web of Science ®Google Scholar
• LiptonAPathophysiology of bone metastases: how this knowledge may lead to therapeutic interventionJ Support Oncol2004220521315328823
   PubMedGoogle Scholar
• LiptonATheriaultRHortobagyiGPamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized controlled trialsCancer20008810829010699899
   PubMed Web of Science ®Google Scholar
• McKiernanJMDeleaTELissMImpact of skeletal complications on total medical care costs in prostate cancer patients with bone metastasesProcAm Soc Clin Oncol200423531A6057
   Web of Science ®Google Scholar
• MartelCLLaraPNRenal cell carcinoma: current status and future directionsCrit Rev Oncol Hematol2003451779012604128
   PubMed Web of Science ®Google Scholar
• MichaelsonMDLeeHKaufmanDSAnnual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized placebo-controlled trialJ Clin Oncol20062418S pt 1220s Abstract #4515
   Google Scholar
• OefeleinMGRicchiutiVConradWSkeletal fractures negatively correlate with overall survival in men with prostate cancerJ Urol20021681005712187209
   PubMed Web of Science ®Google Scholar
• PolascikTJGivenRWMetzerCOpen-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastasesUrology2005661054916286123
   PubMed Web of Science ®Google Scholar
• PlunkettTASmithPRubensRDRisk of complications from bone metastases in breast cancer: implications for managementEur J Cancer2000364768210717523
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDHDuganWZoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesionCancer2004a100364314692022
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus palmidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J200173778711693896
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039817354414534891
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianNSLong-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized phase III double-blind, placebo-controlled trialCancer2004b10026132115197804
   PubMed Web of Science ®Google Scholar
• RossRWSmallEJOsteoporosis in men treated with androgen deprivation therapy for prostate cancerJ Urol20021671952611956415
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDDemersLMZoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancerJ Urol2006176972816890673
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst20029414586812359855
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRLong-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancerJ Natl Cancer Inst2004968798215173273
   PubMed Web of Science ®Google Scholar
• SaadFLiptonAZoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersBJU Internat2005969649
   PubMed Web of Science ®Google Scholar
• SabbatiniPLarsonSMKremerAPrognostic significance of extent of disease in bone in patients with androgen-independent prostate cancerJ Clin Oncol1999179485710071289
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLRisk of fracture after androgen deprivation for prostate cancerN Engl J Med20053521546415647578
   PubMed Web of Science ®Google Scholar
• SmallEJSmithMRSeamanJJCombined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancerJ Clin Oncol200321427784
   Web of Science ®Google Scholar
• SmithMRBoyceSPMoyneurERisk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancerJ Urol2006175136916406890
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol200316920081212771706
   PubMed Web of Science ®Google Scholar
• SmithMRLeeWCBrandmanJGonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancerJ Clin Oncol200523789790316258089
   PubMed Web of Science ®Google Scholar
• SmithMRMcGovernFJZietmanALPamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancerN Engl J Med20013459485511575286
   PubMed Web of Science ®Google Scholar
• SolowayMSHardemanSWHickeyDStratification of patients with metastatic prostate cancer based on extent of disease on initial bone scanCancer1988611952023334948
   PubMed Web of Science ®Google Scholar
• The NCCNProstate Cancer Clinical Practice Guidelines in Oncology© 2006 National Comprehensive Cancer Network, Inc2005 URL: http://www.nccn.org
   Google Scholar
• WardleyADavidsonNBarrett-LeePZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, crossover study of community vs hospital bisphosphonate administrationBr J Cancer20059218697615870721
   PubMed Web of Science ®Google Scholar
• WegnerHClinical experience with zoledronic acid: a urologist’s perspectiveEur Urol Suppl200655512
   Web of Science ®Google Scholar
• WeinfurtKPCastelLDLiYHealth-related quality of life among patients with breast cancer receiving zoledronic acid or palmidronate disodium for metastatic bone lesionsMedical Care2004421647514734954
   PubMed Web of Science ®Google Scholar
• WeinfurtKPLiYCastelLDThe impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancerAnn Oncol200213180
   Google Scholar
• WeinfurtKPLiYCastelLDThe significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancerAnn Oncol2005165798415734776
   PubMed Web of Science ®Google Scholar
• ZekriJAhmedNColemanREThe skeletal metastatic compications of renal cell carcinomaInt J Oncol2001193798211445855
   PubMed Web of Science ®Google Scholar
• Zometa®2006East Hanover, NJNovartis Pharmaceuticals Corporation package insert
   Google Scholar